Biosimilars Roll-Out Propels Fresenius Kabi’s Growth
Firm Credits Biosimilars Contribution As Increases Seen In Q3
As Fresenius delivered its third-quarter results, the firm’s Fresenius Kabi division celebrated sales growth of two-thirds in its Biopharma biosimilars segment amid several solid increases seen in Q3.
